CRSP:NSD-Crispr Therapeutics AG (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 63.79

Change

0.00 (0.00)%

Market Cap

USD 4.94B

Volume

0.95M

Avg Analyst Target

USD 103.88 (+62.84%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


CRSP Stock Forecast & Price:
Based on the Crispr Therapeutics AG stock forecasts from 15 analysts, the average analyst target price for Crispr Therapeutics AG is USD 103.88 over the next 12 months. Crispr Therapeutics AG’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Crispr Therapeutics AG is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Crispr Therapeutics AG’s stock price was USD 63.79. Crispr Therapeutics AG’s stock price has changed by -4.65% over the past week, -0.65% over the past month and -59.08% over the last year.

About Crispr Therapeutics AG (CRSP:NSD)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

N/A

USD65.40B 8.39 6.52
MRNA Moderna Inc

N/A

USD59.64B 4.20 2.94
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.28B 2.86 1.54
SGEN Seagen Inc

N/A

USD33.15B 55.02 -50.53
RPRX Royalty Pharma Plc

N/A

USD28.81B 29.89 16.26
GMAB Genmab AS

N/A

USD21.88B 64.29 5.76
ARGX argenx NV ADR

N/A

USD20.61B N/A -30.89
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CRSP

Symbol Name Weight Mer Price(Change) Market Cap
LS:CA Middlefield Healthcare & .. 0.00 % 0.85 %

N/A

USD0.08B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.40 %

+0.02 (+0.30%)

USD1.29B
BBIG:CA Horizons Global BBIG Tech.. 0.00 % 0.45 %

N/A

N/A
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.82% 79% C+ 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.82% 79% C+ 58% F
Trailing 12 Months  
Capital Gain -59.08% 58% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.08% 58% F 30% F
Trailing 5 Years  
Capital Gain 296.70% 92% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 296.70% 92% A- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 50.47% 82% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.47% 82% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 80.83% 33% F 17% F
Risk Adjusted Return 62.44% 95% A 88% B+
Market Capitalization 4.94B 96% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.19 35% F 49% F
Price/Book Ratio 2.18 45% F 39% F
Price / Cash Flow Ratio 9.17 7% F 29% F
EV/EBITDA 8.76 5% F 31% F
Management Effectiveness  
Return on Equity 15.39% 96% A 80% B-
Return on Invested Capital 18.29% 93% A 86% B
Return on Assets 8.55% 97% A+ 90% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.92 35% F 21% F
Short Percent 15.91% 11% F 11% F
Beta 2.03 17% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.